Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
Portfolio Pulse from
Neurocrine Biosciences presented new data from the KINECT®-HD study, showing that INGREZZA® (valbenazine) capsules consistently reduce chorea in Huntington's disease patients across 19 subgroups, with additional benefits to emotional health.
November 07, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' new data from the KINECT®-HD study shows INGREZZA® is effective in reducing chorea and improving emotional health in Huntington's disease patients, which could positively impact the stock price.
The presentation of positive data from the KINECT®-HD study at a major conference highlights the efficacy of INGREZZA® in treating Huntington's disease, which is likely to enhance investor confidence and positively impact NBIX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100